Participated · Series A · Dec 2025

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.

Participated · Series A · Nov 2025

TandemAI operates a fully integrated drug discovery engine that blends generative AI, molecular dynamics, quantum-mechanics simulations, and an AI-powered SaaS platform called TandemViz with expansive chemistry and biology laboratories. This computation-first approach spans target prediction through clinical candidate nomination and has already produced more than ten high-value drug candidates now in or approaching clinical trials. The company serves a network of over 150 global pharmaceutical partners, helping advance more than 50 innovative pipelines and achieving 10× revenue growth since launch. A recent merger with Perpetual Medicines added deep expertise in peptide and antibody-peptide conjugate discovery, broadening TandemAI’s modality coverage. The firm employs more than 300 professionals and maintains R&D hubs in New York, Boston, and China. Founded in October 2021, TandemAI has raised more than $80 million to date to scale its AI models, wet-lab capacity, and commercial reach.

Participated · Series D · Feb 2025

Founded in 2012, Lambda describes itself as The Superintelligence Cloud and builds gigawatt-scale AI factories and supercomputers for training and inference. The company serves tens of thousands of customers, including AI researchers, enterprises, and hyperscalers. Lambda has invested in technical depth and operational expertise to deploy and manage large-scale AI accelerator infrastructure. The recently closed $1 billion credit facility will fund expansion of its fleet of next-generation NVIDIA AI accelerator servers and increase data center capacity. Management says the financing will add revenue-generating assets and lower the company’s blended cost of capital while enabling quicker execution on strategic infrastructure opportunities. Lambda positions its contracted revenue base and track record of operating at scale as the basis for lender confidence.